Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Aldesleukin + Anti-MAGE-A3-DP4 TCR T-cells + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|Anti-MAGE-A3-DP4 TCR T-cells||Anti-MAGE-A3-DP4 TCR PBL||Anti-MAGE-A3-DP4 TCR T-cells are patient-derived T-lymphocytes that are modified to express a T-cell receptor that recognizes human melanoma antigen 3 (MAGE-A3), which may result in increased killing of MAGE-A3-expressing tumor cells (PMID: 27163739).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02111850||Phase Ib/II||Aldesleukin + Anti-MAGE-A3-DP4 TCR T-cells + Cyclophosphamide + Fludarabine||T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive||Recruiting|